Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.70 |
| ▸ | MTOR | P42345 | 8/20 | 0.70 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.70 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.70 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | PAK4 | O96013 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | FGR | P09769 | 1/20 | 0.70 |
| ▸ | FER | P16591 | 1/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.70 |
| ▸ | JAK1 | P23458 | 1/20 | 0.70 |
| ▸ | TEC | P42680 | 1/20 | 0.70 |
| ▸ | SYK | P43405 | 1/20 | 0.70 |
| ▸ | PRKDC | P78527 | 1/20 | 0.70 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.70 |
| ▸ | BTK | Q06187 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192915 | 1.00 | PIK3CA (0.70) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1192492 | 0.90 | PIK3CA (0.57) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1192493 | 0.90 | PIK3CA (0.57) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1192479 | 0.86 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1192481 | 0.86 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1181496 | 0.85 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1180698 | 0.85 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1180695 | 0.85 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL3656889 | 0.84 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1192012 | 0.83 | PIK3CA (0.73) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207781-B1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-11-28 | — | — | EP | claimed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | claimed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | claimed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | claimed |
| EP-2207781-B1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8158626-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885PIK3CB 3/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | PIK3CA 1/4885PIK3CD 11/4885PIK3CB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.